CClinicalTrials.gg
CompletedNCT03788421Updated Mar 10, 2022

Comparison Between 2 Techniques for Bilateral Salpingectomy

An interventional study of LIGASURE and Clamping and suturing in Sterility, Female, sponsored by Rambam Health Care Campus. Completed at 1 site in Israel. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2022-03-10.

Sponsored by Rambam Health Care Campus · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
51
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

A comparison between 2 techniques for bilateral salpingectomy during cesarean section.

Primary outcomes are total operative time and bilateral completion of the randomized procedure. Secondary outcomes included surgical complications and post operation complications.

Read the detailed description

Ovarian cancer is the most lethal gynecologic malignancy. Major contributors to this high mortality are the lack of effective screening strategies, diagnosis at advanced stage of presentation as well as the high risk of recurrence. In the last years the Gynecologic Associations worldwide have recommended that total salpingectomy be considered for potential ovarian cancer risk reduction in benign gynecologic surgeries after completion of childbearing.

However, the data are limit regarding the Preferred surgical technique during cesarean section.

In this randomized controled trial the investigators will compare between various techniques for bilateral salpingectomy during cesarean section.

Primary outcomes are total operative time and bilateral completion of the randomized procedure. Secondary outcomes included surgical complications and post operation complications.

02

Conditions studied

  • Sterility, Female
03

In context

Infertility

2,506 studies on the registry are indexed under Infertility; 407 are open to participants now.

This study's enrollment of 51 is below the median of 120 across 1,698 interventional studies indexed under Infertility.

Browse Infertility studies →

Lead sponsor

Rambam Health Care Campus is the lead sponsor of 456 studies on the registry; 33 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Participants undergoing elective Cesarean Section and are interested and have signed informed consent regarding bilateral salpingectomy.

Exclusion criteria

Exclusion Criteria:

  • Inability to give informed consent.
  • Preterm delivery (\< 37 weeks' gestation).
  • Fetal demise.
  • Prenatal diagnosis of fetal or placental abnormalities.
  • Previous tubal surgery.
  • The use of anticoagulants.
  • Associated immunosuppressive conditions.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Care provider)
Enrollment
51 participants (actual)

Study arms

  • Active comparator
    Study group

    Women undergoing elective bilateral salpingectomy during cesarean section with LIGASURE.

    Device: LIGASURE

  • Active comparator
    Control group

    Women undergoing elective bilateral salpingectomy during cesarean section with traditional step by step clamping and suturing.

    Procedure: Clamping and suturing

Interventions

  • DeviceLIGASURE

    Electricity based cautery tool used during both laparoscopic and open surgery for optimal hemostasis.

  • ProcedureClamping and suturing

    Step by step clamping and suturing of the mesosalpinx until achievement of total salpingectomy.

06

What researchers measure

Primary outcomes

  1. Total salpingectomy time.

    Time in minutes from beginning of salpingectomy procedure until end of the salpingectomy procedure.

    Time frame: Up to 1 week from recruitment

Secondary outcomes

  1. Bleeding during salpingectomy

    Estimated amount of bleeding in milliliters during the salpingectomy procedure

    Time frame: Up to 4 hours from the beginning of the procedure

  2. Bleeding during cesarean section

    Estimated amount of bleeding in milliliters during the whole cesarean section.

    Time frame: Up to 4 hours from the beginning of the procedure

  3. Hemoglobin level

    Changes in hemoglobin level before and after surgery

    Time frame: Up to 5 days from surgery

  4. Blood transfusion rate

    The rate of blood transfusion post cesarean section

    Time frame: Up to 5 days from surgery

  5. Postoperative stay

    The length of maternal postoperative stay.

    Time frame: Up to 2 weeks from surgery

  6. Visual analogue score

    Pain scoring between 0-10 post-surgery

    Time frame: Up to 2 weeks from surgery

  7. Wound complications

    The rate of wound complications postpartum.

    Time frame: Up to 2 weeks from surgery

  8. Need for opioids

    The rate of opioid treatment postpartum

    Time frame: Up to 2 weeks from surgery

07

Study locations

1 site
  • Rambam health care campus
    Haifa, Israel
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 10, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03788421
Lead sponsor
Rambam Health Care Campus
Responsible party
Yaniv Zipori MD (Principal Investigator, Rambam Health Care Campus) — Principal investigator
First posted
Dec 27, 2018
Start date
Jan 1, 2019
Primary completion
Jan 1, 2021
Completion
Sep 1, 2021
Last update
Mar 10, 2022

Study contacts

Yaniv Zipori, MD
principal investigator · Rambam healthcare campus

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion